L-Asparaginase
- 26 March 1970
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 282 (13) , 732-734
- https://doi.org/10.1056/nejm197003262821307
Abstract
L-ASPARAGINASE affords a unique approach to the chemotherapy of malignant neoplasms by exploiting a metabolic difference between tumor cells and host cells.Historical BackgroundIn 1953 Kidd1 noted that normal guinea-pig serum has antitumor activity, and Broome2 subsequently showed that the active antitumor substance is L-asparaginase, which is present in high concentration in the serum of the guinea pig and its close relatives. Dolowy and his associates3 used purified guinea-pig serum to treat a boy with acute lymphoblastic leukemia and obtained an objective response. The discovery of Escherichia coli L-asparaginase with antitumor activity presented a source of enzyme in sufficient . . .Keywords
This publication has 5 references indexed in Scilit:
- Serine Requirement in Leukemic and Normal Blood CellsScience, 1969
- DIVISION OF MICROBIOLOGY: L‐ASPARAGINASE: THE EVOLUTION OF A NEW TUMOR INHIBITORY AGENT*Transactions of the New York Academy of Sciences, 1968
- L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemiaJAMA, 1967
- Toxic and antineoplastic effects of l-asparaginase: Study of mice with lymphoma and normal monkeys and report on a child with leukemiaCancer, 1966
- REGRESSION OF TRANSPLANTED LYMPHOMAS INDUCED IN VIVO BY MEANS OF NORMAL GUINEA PIG SERUMThe Journal of Experimental Medicine, 1953